This review explores analytical methods for measuring vildagliptin levels in patients with type 2 diabetes, highlighting both effectiveness and tolerability.
Vildagliptin is an orally active, potent, and selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, shown to be effective and well tolerated in patients with Type 2 Diabetes Mellitus (T2DM) as either monotherapy or in combination with other anti-diabetic agents. Vildagliptin is used to treat type 2 diabetes mellitus, typically in conjunction with diet and exercise. Vildagliptin is usually administered orally, with a common dosing regimen of 50 mg twice daily. It can be taken with or without food; however, it is important to take it consistently at the same time each day for optimal effectiveness. This study focuses on the most recent advancements in analytical methods for determining the presence of Vildagliptin in different biological media, such as human plasma and urine, as well as in bulk and commercial dose forms. The following analytical techniques will be fully investigated in this paper: High-pressure Liquid Chromatography (HPLC), High Efficiency Thin Layer Chromatography (HPTLC), liquid chromatography coupled to a tandem mass spectrometry system (LC-MS), and electrophoresis. These techniques include several parameters, such as the following: matrix, dynamic phase composition, permanent phase RF value for sensing frequency, retention duration, DL, carrier gas, flow rate, capillary wavelength, separation voltage, temperature, and pressure.
No takes yet. Share an insight, caveat, or question.
Pritam et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: